Asset Details
Do you wish to reserve the book?
Comparison of biodegradable and metal occluders in patients with PFO and migraine: study design and rationale of BioMetal Trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparison of biodegradable and metal occluders in patients with PFO and migraine: study design and rationale of BioMetal Trial
Do you wish to request the book?
Comparison of biodegradable and metal occluders in patients with PFO and migraine: study design and rationale of BioMetal Trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparison of biodegradable and metal occluders in patients with PFO and migraine: study design and rationale of BioMetal Trial
2025
Overview
Background
The association between migraine and patent foramen ovale (PFO) has led to investigations into percutaneous PFO closure as a potential therapeutic avenue. While existing trials with metal occluders have shown promise in reducing migraine burden, concerns over long-term complications and the impact of metal devices on migraine exacerbation have prompted the development of biodegradable alternatives.
Methods
The Comparison of Biodegradable and Metal Occluders in Patients with PFO and Migraine (BioMetal) trial is a prospective, multicenter, single-blind, randomized controlled, superiority study comparing a biodegradable occluder with a nickel-titanium alloy occluder in PFO patients with medication-refractory migraine with aura (ClinicalTrials.gov Identifier: NCT06203873). A total of 400 participants will be enrolled, randomized 1:1 to receive either the biodegradable or metal devices, and followed up for 24 months post-randomization. The primary endpoint is the change in monthly migraine days at 12 months compared to baseline.
Discussion
The BioMetal trial aims to address the ongoing debate surrounding PFO closure for migraine relief by evaluating the efficacy and safety of biodegradable versus metal devices, with the goal of providing valuable insights into the optimal approach for PFO closure in PFO patients with medication-refractory migraine with aura. The potential implications extend beyond migraine management, highlighting the significance of biocompatible and sustainable materials in interventional cardiology. Completion of this study is anticipated to inform future clinical practice and guide therapeutic strategies in this complex condition.
Trial registration
ClinicalTrials.gov NCT06203873 (
https://clinicaltrials.gov/study/NCT06203873
). Registered on January 3, 2024
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Adult
/ Alloys
/ Female
/ Foramen Ovale, Patent - complications
/ Foramen Ovale, Patent - surgery
/ Foramen Ovale, Patent - therapy
/ Heart
/ Humans
/ Male
/ Medicine
/ Migraine
/ Migraine with Aura - diagnosis
/ Migraine with Aura - etiology
/ Multicenter Studies as Topic
/ Nickel
/ Randomized Controlled Trials as Topic
/ Statistics for Life Sciences
/ Titanium
